Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $20,430.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,500 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was bought at an average cost of $13.62 per share, with a total value of $20,430.00. Following the completion of the purchase, the chief executive officer owned 5,610,702 shares of the company’s stock, valued at $76,417,761.24. This represents a 0.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Wednesday, July 29th, Snehal Patel acquired 700 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $13.10 per share, for a total transaction of $9,170.00.
• On Thursday, July 23rd, Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $13.14 per share, for a total transaction of $32,850.00.
• On Friday, July 24th, Snehal Patel bought 1,100 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $12.88 per share, for a total transaction of $14,168.00.

Greenwich LifeSciences Stock Performance

GLSI stock opened at $13.50 on Friday. Greenwich LifeSciences, Inc. has a fifty-two week low of $7.78 and a fifty-two week high of $34.10. The company has a market capitalization of $198.18 million, a price-to-earnings ratio of -8.60 and a beta of 1.40. The business’s 50 day moving average price is $20.79 and its two-hundred day moving average price is $24.04.

Analyst Ratings Changes

GLSI has been the topic of several recent research reports. Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Finally, HC Wainwright boosted their target price on shares of Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $57.00.

Hedge Funds Weigh In On Greenwich LifeSciences

Large investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after purchasing an additional 1,322 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares during the last quarter. Wells Fargo & Company MN increased its position in Greenwich LifeSciences by 109.6% during the 4th quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after buying an additional 4,102 shares in the last quarter. Strs Ohio bought a new position in Greenwich LifeSciences during the 1st quarter valued at approximately $177,000. Finally, Jane Street Group LLC purchased a new position in Greenwich LifeSciences during the fourth quarter valued at $203,000. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.